Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

FEMARA® (letrozole) has a well-established favorable safety profile in postmenopausal women after adjuvant tamoxifen treatment

FEMARA® is the only AI with demonstrated safety from a large-scale extended adjuvant trial versus placebo1-4

The incidence of the most common (>5% of patients) adverse events seen with FEMARA® were generally comparable vs placebo.1-4

Most frequently reported AEs during chronic therapy (>5% in any group)1

Femara | Most frequently reported AEs during chronic therapy

In the MA-17 lipid substudy, effects of FEMARA® were comparable to placebo1,5,6

FEMARA® had no significant effect on total, HDL, and LDL cholesterol, triglycerides, or lipoprotein(a).6

After adjuvant tamoxifen therapy, choose FEMARA® (letrozole) for extended protection accompanied by a favorable safety profile.1-4

To read about the unique efficacy profile of FEMARA® in the initial adjuvant setting, click here.

Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
Click here for Important Safety Information for FEMARA®.
References: 1. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271. 2. Arimidex® (anastrazole) [summary of product characteristics]. Luton, UK: AstraZeneca UK Limited; 2007. 3. Aromasin® (exemestane) [summary of product characteristics]. Sandwich, UK: Pharmacia Ltd; 2008. 4. Jakesz R, Greil R, Gnant M, et al; for the Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845-1853. 5. FEMARA® [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 6. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105(suppl 1):45-53.